Clinical Trials
192
30 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1834
Active, not recruiting
8
4.2%
Completed
74
38.5%
Enrolling By Invitation
2
1.0%
Not yet recruiting
20
10.4%
Recruiting
48
25.0%
Terminated
9
4.7%
Unknown
29
15.1%
Withdrawn
2
1.0%
No approval data available
- VUB researchers mapped the healthy human pancreas at cellular resolution, revealing that the large drainage ducts possess a layered structure rather than a simple single-cell composition. - A rare cell group was discovered in healthy tissue that already bears strong similarities to the most aggressive pancreatic tumor cells, opening avenues for early detection. - In adenosquamous carcinoma (ASCP), the rare but aggressive variant, the specific cell types and spatial architecture of the healthy duct are almost perfectly preserved, unlike in classical PDAC where organization is obliterated. - The findings, published in Gut, argue for distinct therapeutic strategies for ASCP patients, who currently receive identical treatment to those with the more common PDAC variant.
- Dropshot Therapeutics has successfully completed preclinical milestones for its renal disease target using etherna's mRNA and lipid nanoparticle platforms, marking a major advancement in RNA-based therapeutics for kidney diseases. - The collaboration will now focus on manufacturing GMP-grade material for IND-enabling studies and Phase I clinical trials, with clinical campaign launch planned for 2027. - etherna's decade of expertise in mRNA chemistry and customizable lipid nanoparticles has enabled Dropshot to validate its platform technologies and move toward addressing unmet medical needs in renal and cardiac diseases.
- A 27-year-old man produced mature sperm after testicular tissue frozen at age 10 was re-transplanted 16 years later, marking the first such success in humans. - The breakthrough trial, led by Prof Ellen Goossens at Vrije Universiteit Brussel, demonstrates proof-of-principle that cryopreserved prepubertal testicular tissue can restore sperm production. - Separately, Karolinska Institutet researchers showed that early germ cells can be generated from preserved testicular tissue via induced pluripotent stem cell reprogramming, even after cancer treatment damage. - Over 3,000 patients worldwide have testicular tissue banked, and UK clinicians expect to begin similar transplants imminently.
- An international consortium has discovered DOPA decarboxylase (DDC) as a highly accurate cerebrospinal fluid biomarker for diagnosing Parkinson's disease and dementia with Lewy bodies, achieving 94-97% diagnostic accuracy. - DDC levels in cerebrospinal fluid were up to 2.5 times higher in patients with Parkinson's disease and dementia with Lewy bodies compared to healthy controls, and nearly twice as high as in Alzheimer's disease patients. - The biomarker showed strong correlation with alpha-synuclein pathology in post-mortem brain tissue, reinforcing its biological relevance for these neurodegenerative conditions. - This breakthrough addresses a critical clinical need, as dementia with Lewy bodies is frequently misdiagnosed due to overlapping symptoms with other forms of dementia.
• A 26-year-old bone cancer survivor has received the first known transplant of sperm-producing stem cells preserved from his childhood, marking a significant advancement in fertility preservation for pediatric cancer patients. • Approximately one-third of childhood cancer survivors face infertility from treatments, with prepubertal patients having limited options as they cannot bank mature reproductive cells before therapy. • The experimental procedure, developed at the University of Pittsburgh Medical Center, follows successful animal studies and represents a potential breakthrough in oncofertility, though researchers caution results remain uncertain.
